Bortezomib in autoimmune hemolytic anemia and beyond - Raffaella Pasquale, Juri Alessandro Giannotta, Wilma Barcellini, Bruno Fattizzo, 2021
Abstract Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma...
0pubmed
In this review, we collected available literature on bortezomib use in AIHA and in other immune-mediated hematologic and non-hematologic diseases. Overall, most experiences highlight bortezomib efficacy even in multi-relapsed/refractory patients and suggest to consider its use in AIHA after rituximab failure.
Salvage therapy with "Dara‐KDT‐P(A)CE" in heavily pretreated, high‐risk, proliferative, relapsed/refractory Multiple Myeloma
Source : https://onlinelibrary.wiley.com/doi/10.1002/hon.2949
Corresponding Author Department of Internal Medicine II, Würzburg University of Hospital, University of Würzburg, Germany Correspondence Xiang Zhou MD, Department of Internal Medicine II Würzburg University Hospital Oberdürrbacher Street 6...
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34270825/
doi: 10.1111/ejh.13690. Online ahead of print. 1 Medizinische Klinik, München Klinik Schwabing, Munich, Germany. 2 Asklepios Tumorzentrum Hamburg, AK Altona und AK St. Georg, Hamburg, Germany. 3 Medizinische Klinik und...
Trying to stomach multiple myeloma: A case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34123929/
We report a case of a 51-year-old male with minimal past medical history who presented to his primary care provider with nausea, vomiting and constipation in the outpatient setting. Concomitantly,...
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34131635/
Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with...